- Title
- Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and markov models
- Creator
- Gao, Lan; Li, Shu-Chuen
- Relation
- Applied Health Economics and Health Policy Vol. 17, Issue 3, p. 371-380
- Publisher Link
- http://dx.doi.org/10.1007/s40258-018-0452-0
- Publisher
- Adis International
- Resource Type
- journal article
- Date
- 2019
- Description
- Objectives: To assess the cost-effectiveness of nivolumab for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) progressed on or after platinum-based chemotherapy using a modelled economic evaluation. Methods: Both partition survival (PS) and Markov models, comprised of three health states, were adopted to evaluate the cost-effectiveness of nivolumab compared to docetaxel from an Australian healthcare system perspective with a 6-year time horizon. Reconstructed individual patient data (IPD) were derived from published Kaplan-Meier curves from the pivotal trial for overall survival (OS) and progression-free survival (PFS) using a validated algorithm. Best-fitting survival curves were selected to extrapolate the OS, PFS and post-progression survival (PPS) beyond trial duration. Expected costs and health outcomes [i.e. quality-adjusted life year (QALY), and life year (LY)] associated with each of the health states (i.e. PF, PD and dead) were accrued over the time horizon. Both deterministic and probabilistic sensitivity analyses were undertaken. Results: Nivolumab was associated with both higher costs and benefits in both PS and Markov models. In particular, from the PS model, nivolumab cost an additional A$198,862/QALY and A$181,623/LY gained. The Markov model showed that nivolumab had an incremental cost-effectiveness ratio (ICER) of A$220,029/QALY and A$193,459/LY, respectively. The sensitivity analyses showed base-case results were sensitive to the extrapolation approach, duration of treatment, cost of nivolumab and time horizon modelled. Conclusions: Using an often-quoted willingness-to-pay per QALY threshold in Australia (i.e. A$50,000), the treatment with nivolumab cannot be considered cost-effective. It might be funded publicly by special arrangements given unmet clinical needs for patients.
- Subject
- nivolumab; lung cancer; markov models; costs; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1466701
- Identifier
- uon:47631
- Identifier
- ISSN:1175-5652
- Language
- eng
- Reviewed
- Hits: 479
- Visitors: 478
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|